Genflow Biosciences announced it has launched a new development program targeting Werner syndrome, a rare premature aging disorder. According to the company, the program will focus on addressing genomic instability, which it claims is a key factor in the disease’s progression and broader aging processes.
The company said the program aims to develop gene therapies that may correct or compensate for mutations in the WRN gene, which is associated with accelerated aging and increased risk of age-related diseases. Genflow Biosciences claims this strategy aligns with its broader mission to develop therapeutics that target the biology of aging.
Genflow Biosciences also said Werner syndrome represents a well-defined clinical model to explore interventions targeting DNA repair and genomic maintenance pathways. According to the company, insights gained from this program could potentially inform therapies for more common age-associated conditions.
The company claims it will leverage its expertise in gene therapy and aging biology to advance preclinical research and identify candidates for further development. Genflow Biosciences said this new program underscores its commitment to developing therapies that address underlying mechanisms of aging and genetic instability.
